[March 03, 2015]

Research and Markets: Metastatic Prostate Cancer Therapeutics Pipeline Review 2015 - 12 Companies & 19 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/bctd5d/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stge and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Actinium Pharmaceuticals, Inc.
• Camurus AB
• Colby Pharmaceutical Company
• Eli Lilly and Company
• Fountain Biopharma Inc.
• Johnson & Johnson
• MedImmune, LLC
• MEI Pharma, Inc.
• OncoMax
• OXiGENE, Inc.
• Progenics Pharmaceuticals, Inc.
• ValiRx Plc

Drug Profiles

• abiraterone acetate
• Actimab-P
• CADD-522
• Cell Therapy to Target (News - Alert) PSMA for Metastatic Prostate Cancer
• CPC-410
• FB-704A
• KGP-94
• leuprolide acetate
• LU-901
• LY-2495655
• MEDI-6469
• MIP-1095
• MVI-118
• OMRCA-01
• pracinostat
• Recombinant Protein for Oncology
• VAC-1
• Vaccine For Oncolytic Newcastle Disease Virus
• VAL-201

For more information visit http://www.researchandmarkets.com/research/bctd5d/metastatic

[ Back To TMCnet.com's Homepage ]